High-density lipoproteins (HDL) are present in stenotic aortic valves and may interfere with the mechanisms of valvular calcification

Atherosclerosis

Volumn 219, Issue 2, 2011, Pages 538-544

  Lommi, Jaakko I ^a   Kovanen, Petri T ^a   Jauhiainen, Matti ^b   Lee Rueckert, Miriam ^a   Kupari, Markku ^c   Helske, Satu ^a  

^a WIHURI RESEARCH INSTITUTE   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Aortic valve stenosis; ApoA I; HDL; OPG; TNF

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; BIGLYCAN; CHYMASE; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA;

AORTA VALVE CALCIFICATION; AORTA VALVE DISEASE; AORTA VALVE REPLACEMENT; AORTA VALVE STENOSIS; ARTICLE; AUTOPSY; CALCIFICATION; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MYOFIBROBLAST; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE LEVEL;

AORTIC VALVE; AORTIC VALVE STENOSIS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; APOLIPOPROTEINS E; AUTOPSY; CALCINOSIS; CASE-CONTROL STUDIES; CELLS, CULTURED; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FINLAND; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION MEDIATORS; LIPOPROTEINS, HDL; MYOFIBROBLASTS; OSTEOPROTEGERIN; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 82955245370     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.08.027     Document Type: Article

References (37)

1. Stewart B.F., Siscovick D., Lind B.K., et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular health study. J Am Coll Cardiol 1997, 29:630-634.
2. Lindroos M., Kupari M., Heikkila J., Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 1993, 21:1220-1225.
3. Lindroos M., Kupari M., Valvanne J., Strandberg T., Heikkila J., Tilvis R. Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J 1994, 15:865-870.
4. Yilmaz M.B., Guray U., Guray Y., et al. Lipid profile of patients with aortic stenosis might be predictive of rate of progression. Am Heart J 2004, 147:915-918.
5. Freeman R.V., Otto C.M. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 2005, 111:3316-3326.
6. Otto C.M., Kuusisto J., Reichenbach D.D., Gown A.M., O'Brien K.D. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994, 90:844-853.
7. O'Brien K.D., Reichenbach D.D., Marcovina S.M., Kuusisto J., Alpers C.E., Otto C.M. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996, 16:523-532.
8. Olsson M., Thyberg J., Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 1999, 19:1218-1222.
9. Helske S., Lindstedt K.A., Laine M., et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 2004, 44:1859-1866.
10. Mohler E.R., Gannon F., Reynolds C., Zimmerman R., Keane M.G., Kaplan F.S. Bone formation and inflammation in cardiac valves. Circulation 2001, 103:1522-1528.
11. Otto C.M., Burwash I.G., Legget M.E., et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation 1997, 95:2262-2270.
12. Cowell S.J., Newby D.E., Prescott R.J., et al. Scottish aortic stenosis and lipid lowering trial impact on regression (SALTIRE) investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005, 352:2389-2397.
13. Rossebo A.B., Pedersen T.R., Boman K., et al. SEAS investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008, 359:1343-1356.
14. Chan K.L., Teo K., Dumesnil J.G., Ni A., Tam J. ASTRONOMER investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010, 121:306-314.
15. Rajamannan N.M., Subramaniam M., Stock S.R., et al. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart 2005, 91:806-810.
16. Florentin M., Liberopoulos E.N., Wierzbicki A.S., Mikhailidis D.P. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008, 23:370-378.
17. Busseuil D., Shi Y., Mecteau M., et al. Regression of aortic valve stenosis by ApoA-I mimetic peptide infusions in rabbits. Br J Pharmacol 2008, 154:765-773.
18. Speidl W.S., Cimmino G., Ibanez B., et al. Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model. Eur Heart J 2010, 31:2049-2057.
19. Kaden J.J., Bickelhaupt S., Grobholz R., et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 2004, 36:57-66.
20. Rosenhek R., Binder T., Porenta G., et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000, 343:611-617.
21. O'Brien K.D., Olin K.L., Alpers C.E., et al. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation 1998, 98:519-527.
22. Kovanen P.T., Pentikainen M.O. Circulating lipoproteins as proinflammatory and anti-inflammatory particles in atherogenesis. Curr Opin Lipidol 2003, 14:411-419.
23. Mineo C., Deguchi H., Griffin J.H., Shaul P.W. Endothelial and antithrombotic actions of HDL. Circ Res 2006, 98:1352-1364.
24. Cockerill G.W., Rye K.A., Gamble J.R., Vadas M.A., Barter P.J. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995, 15:1987-1994.
25. Watson A.D., Berliner J.A., Hama S.Y., et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995, 96:2882-2891.
26. Chiesa G., Parolini C., Sirtori C.R. Acute effects of high-density lipoproteins: biochemical basis and clinical findings. Curr Opin Cardiol 2008, 23:379-385.
27. Kaden J.J., Dempfle C.E., Grobholz R., et al. Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc Pathol 2005, 14:80-87.
28. Helske S., Oksjoki R., Lindstedt K.A., et al. Complement system is activated in stenotic aortic valves. Atherosclerosis 2008, 196:190-200.
29. Kaden J.J., Kilic R., Sarikoc A., et al. Tumor necrosis factor alpha promotes an osteoblast-like phenotype in human aortic valve myofibroblasts: a potential regulatory mechanism of valvular calcification. Int J Mol Med 2005, 16:869-872.
30. Zuckerman S.H., Evans G.F., O'Neal L. Cytokine regulation of macrophage apo E secretion: opposing effects of GM-CSF and TGF-beta. Atherosclerosis 1992, 96:203-214.
31. Schmidt A., Lorkowski S., Seidler D., Breithardt G., Buddecke E. TGF-beta1 generates a specific multicomponent extracellular matrix in human coronary SMC. Eur J Clin Invest 2006, 36:473-482.
32. Helske S., Laine M., Kupari M., et al. Increased expression of profibrotic neutral endopeptidase and bradykinin type 1 receptors in stenotic aortic valves. Eur Heart J 2007, 28:1894-1903.
33. Helske S., Syvaranta S., Kupari M., et al. Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves. Eur Heart J 2006, 27:1495-1504.
34. Van Lenten B.J., Hama S.Y., de Beer F.C., et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995, 96:2758-2767.
35. Lee-Rueckert M., Kovanen P.T. Mast cell proteases: physiological tools to study functional significance of high density lipoproteins in the initiation of reverse cholesterol transport. Atherosclerosis 2006, 189:8-18.
36. Helske S., Otto C.M. Lipid lowering in aortic stenosis: still some light at the end of the tunnel?. Circulation 2009, 119:2653-2655.
37. Helske S., Kupari M., Lindstedt K.A., Kovanen P.T. Aortic valve stenosis: an active atheroinflammatory process. Curr Opin Lipidol 2007, 18:483-491.